Advertisement

Statins and Demyelination

  • M. S. Weber
  • S. S. Zamvil
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 318)

Statins are inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase, which are widely prescribed for their cholesterol-lowering properties in order to reduce atherogenesis and cardiovascular morbidity. Moreover, statins have been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. Statins appear to alter immune function largely independent of lipid lowering and rather through inhibition of posttranslational protein prenylation of small regulatory GTP-binding proteins. In experimental autoimmune encephalomyelitis (EAE), the murine model for multiple sclerosis (MS), statins were shown to reverse established paralysis and to exert synergistic benefit in combination with agents approved for MS therapy. Based upon these encouraging findings in treatment of EAE, statins are now being tested in clinical trials in patients with MS.

Keywords

Multiple Sclerosis Experimental Autoimmune Encephalo Major Histocompatibility Complex Class Glatiramer Acetate Statin Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anonymous (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 s). Lancet 344: 1383-1389Google Scholar
  2. 2.
    Anonymous (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. N Engl J Med 339:1349-1357CrossRefGoogle Scholar
  3. 3.
    Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383:787-793CrossRefPubMedGoogle Scholar
  4. 4.
    Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R, Zipp F (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 197:725-733CrossRefPubMedGoogle Scholar
  5. 5.
    Begolka WS, Vanderlugt CL, Rahbe SM, Miller SD (1998) Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 161:4437-4446PubMedGoogle Scholar
  6. 6.
    Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F (1998) HMGCOA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18:1671-1678PubMedGoogle Scholar
  7. 7.
    Birnbaum G, Irfan A (2005) A double blind, placebo controlled combination trial of interferon beta 1a (Rebif) and atorvastatin (Lipitor) in patients with relapsing remitting multiple sclerosis. Paper presented at the AAN, 2005Google Scholar
  8. 8.
    Bonet S, Garcia Villena I, Tomas Santos P, Tapia Mayor I, Gussinye Canabal P, Mundet Tuduri X (1999) When and how do we treat our hypercholesterolemic patients?. Aten Primaria 24:397-403PubMedGoogle Scholar
  9. 9.
    Cannella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37:424-435CrossRefPubMedGoogle Scholar
  10. 10.
    Chang CH, Flavell RA (1995) Class ii transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 181:765-767CrossRefPubMedGoogle Scholar
  11. 11.
    Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA (2000) Glatiramer acetate (Copaxone) induces degenerate, th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105:967-976CrossRefPubMedGoogle Scholar
  12. 12.
    Dunn SE, Youssef S, Goldstein MJ, Prod’homme T, Weber MS, Zamvil SS, Steinman L (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 203:401-412CrossRefPubMedGoogle Scholar
  13. 13.
    Dustin ML, Shaw AS (1999) Costimulation: building an immunological synapse. Science 283:649-650CrossRefPubMedGoogle Scholar
  14. 14.
    Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH (2001) Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 56:931-933CrossRefPubMedGoogle Scholar
  15. 15.
    Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH (2002) Statins and risk of polyneuropathy: a case-control study. Neurology 58:1333-1337PubMedGoogle Scholar
  16. 16.
    Ganne F, Vasse M, Beaudeux JL, Peynet J, Francois A, Mishal Z, Chartier A, Tobelem G, Vannier JP, Soria J, Soria C (2000) Cerivastatin, an inhibitor of HMG-COA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb Haemost 84:680-688PubMedGoogle Scholar
  17. 17.
    Ginsberg HN (1998) Effects of statins on triglyceride metabolism. Am J Cardiol 81:32B-35BCrossRefPubMedGoogle Scholar
  18. 18.
    Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585-2590CrossRefPubMedGoogle Scholar
  19. 19.
    Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P (2003) Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 17:905-907PubMedGoogle Scholar
  20. 20.
    Ifergan I, Wosik K, Cayrol R, Kebir H, Auger C, Bernard M, Bouthillier A, Moumdjian R, Duquette P, Prat A (2006) Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 60:45-55CrossRefPubMedGoogle Scholar
  21. 21.
    Jorritsma PJ, Brogdon JL, Bottomly K (2003) Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4+ T cells. J Immunol 170:2427-2434PubMedGoogle Scholar
  22. 22.
    Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI et al (1995) Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-2540PubMedGoogle Scholar
  23. 23.
    Khoury SJ, Hancock WW, Weiner HL (1992) Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 176:1355-1364CrossRefPubMedGoogle Scholar
  24. 24.
    Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y, Jalili F, Bar-Or A (2004) Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 172:7144-7153PubMedGoogle Scholar
  25. 25.
    Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA et al (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627CrossRefPubMedGoogle Scholar
  26. 26.
    Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177:566-573PubMedGoogle Scholar
  27. 27.
    Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402CrossRefPubMedGoogle Scholar
  28. 28.
    McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015-2021CrossRefPubMedGoogle Scholar
  29. 29.
    Menge T, Hartung HP, Stuve O (2005) Statins - a cure-all for the brain? Nat Rev Neurosci 6:325-331CrossRefPubMedGoogle Scholar
  30. 30.
    Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP (2007) Simvastatin regulates oligodendroglial process dynamics and survival. Glia 55:130-143CrossRefPubMedGoogle Scholar
  31. 31.
    Mix E, Ibrahim SM, Pahnke J, Glass A, Mazon-Pelaez I, Lemcke S, Koczan D, Gimsa U, Bansemer S, Scheel T, Karopka T, Bottcher T, Muller J, Dazert E, Antipova V, Hoffrogge R, Wree A, Zschiesche M, Strauss U, Kundt G, Warzok R, Gierl L, Rolfs A (2006) 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE. J Autoimmun 27:251-265CrossRefPubMedGoogle Scholar
  32. 32.
    Nath N, Giri S, Prasad R, Singh AK, Singh I (2004) Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy. J Immunol 172:1273-1286PubMedGoogle Scholar
  33. 33.
    Neuhaus O, Farina C, Wekerle H, Hohlfeld R (2001) Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702-708PubMedGoogle Scholar
  34. 34.
    Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990-997CrossRefPubMedGoogle Scholar
  35. 35.
    Pahan K, Sheikh FG, Namboodiri AM, Singh I (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100:2671-2679CrossRefPubMedGoogle Scholar
  36. 36.
    Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I (2005) HMG-COA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J 19:1407-1421CrossRefPubMedGoogle Scholar
  37. 37.
    Paintlia AS, Paintlia MK, Singh I, Singh AK (2006) Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta- d- ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol 169:1012-1025CrossRefPubMedGoogle Scholar
  38. 38.
    Sadeghi MM, Tiglio A, Sadigh K, O’Donnell L, Collinge M, Pardi R, Bender JR (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-COA reductase inhibitors. Transplantation 71:1262-1268CrossRefPubMedGoogle Scholar
  39. 39.
    Schulz JG, Bosel J, Stoeckel M, Megow D, Dirnagl U, Endres M (2004) HMG-COA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem 89:24-32CrossRefPubMedGoogle Scholar
  40. 40.
    Sena A, Pedrosa R, Graca Morais M (2003) Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 250:754-755CrossRefPubMedGoogle Scholar
  41. 41.
    Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-540CrossRefPubMedGoogle Scholar
  42. 42.
    Stanislaus R, Gilg AG, Singh AK, Singh I (2002) Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by lovastatin. Neurosci Lett 333:167-170CrossRefPubMedGoogle Scholar
  43. 43.
    Steinman L (2004) Immune therapy for autoimmune diseases. Science 305:212-216CrossRefPubMedGoogle Scholar
  44. 44.
    Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, Prod’homme T, Sobel RA, Steinman L, Zamvil SS (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116:1037-1044CrossRefPubMedGoogle Scholar
  45. 45.
    Stüve O, Youssef S, Weber MS, Prod’homme T, Dunn SE, Steinman L, Zamvil SS (2004) The combination of atorvastatin and glatiramer acetate induces a Th2 phenotype and shows enhanced clinical efficacy in experimental autoimmune encephalomyelitis. J Neuroimmunol 154:77Google Scholar
  46. 46.
    Takai Y, Sasaki T, Matozaki T (2001) Small GTP-binding proteins. Physiol Rev 81:153-208PubMedGoogle Scholar
  47. 47.
    Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608CrossRefPubMedGoogle Scholar
  48. 48.
    Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, Zipp F (2005) Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol 174:5630-5635PubMedGoogle Scholar
  49. 49.
    Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C (2004) Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127:1370-1378CrossRefPubMedGoogle Scholar
  50. 50.
    Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692CrossRefPubMedGoogle Scholar
  51. 51.
    Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, Ludwig J, Berger T, Steinkasserer A, Daniel WG, Garlichs CD (2004) HMG-COA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172:85-93CrossRefPubMedGoogle Scholar
  52. 52.
    Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21:75-80CrossRefPubMedGoogle Scholar
  53. 53.
    Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS (2002) The HMG-COA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84CrossRefPubMedGoogle Scholar
  54. 54.
    Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T (2003) 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23:11104-11111PubMedGoogle Scholar
  55. 55.
    Zeinstra E, Wilczak N, Chesik D, Glazenburg L, Kroese FG, De Keyser J (2006) Simvastatin inhibits interferon-gamma-induced MHC class II up-regulation in cultured astrocytes. J Neuroinflammation 3:16CrossRefPubMedGoogle Scholar
  56. 56.
    Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • M. S. Weber
    • 1
  • S. S. Zamvil
    • 1
  1. 1.Department of NeurologyUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations